Handelsavisen
prelaunch
Companies Healthcare ELUT.O
EL
ELUT.O NASDAQ Diversified Pharmaceuticals

Elutia Inc

$0,87
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
38,3M USD
P/E
0,9x
EV / Rev
3,6x
Div yield
Op margin
-126,7 %
ROE
35,8 %
Net margin
-268,8 %
Debt / equity
-0,44
Beta
52w range
Volume
310
Day range
$1,12–$1,17
Prev close
$1,14
Open
$1,15
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Elutia Inc is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the areas of women's health and urology.

Business. Elutia Inc (ELUT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Elutia is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are provided in the available data.

Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target5,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
5,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
0,9x
P/E
Analysts
Buy
1 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
35,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ELUT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ELUT.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Elutia Inc (ELUT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Elutia is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are provided in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Pharmaceuticals
    AI synthesis
    GENERATED

    Elutia's capital structure is highly leveraged, with total liabilities of $85.66 million and total equity of -$50.30 million, indicating a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.63 and a negative operating cash flow of -$2.64 million. The debt-to-equity ratio of -0.44 further highlights the company's reliance on debt financing, which is atypical for a firm with negative equity.

    Profitability metrics are concerning, with a net loss of $17.99 million and an operating loss of $8.48 million. The return on equity (ROE) of 0.3577 is positive but misleading due to the negative equity base. The return on assets (ROA) of -0.5089 indicates that the company is not generating returns from its asset base. Gross profit of $2.84 million is significantly lower than revenue of $6.69 million, suggesting high cost of goods sold or low pricing power.

    Elutia's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-specific revenue data, but the lack of diversification increases exposure to market-specific risks. The absence of geographic breakdown suggests a potential concentration risk, particularly if the company's products are regionally dependent.

    The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The negative operating and free cash flows indicate a lack of internal funding for growth initiatives. The capital expenditure of -$15,000 is minimal, suggesting limited investment in long-term growth. Analysts have assigned a mean price target of $5.00, which is significantly higher than the current market price of $1.04, but the lack of strong buy recommendations (0) and the presence of only one buy recommendation suggest cautious sentiment.

    Risk factors include high liquidity risk due to negative net cash and a weak balance sheet. The company's dilution risk is currently low, but the negative equity position and high debt levels could necessitate future equity raises, which would dilute existing shareholders. The risk assessment flags a negative net cash position after subtracting total debt, which is a red flag for short-term solvency.

    Recent events include the publication of the latest financial data, which shows continued losses and a deteriorating balance sheet. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational performance. The lack of recent positive developments or guidance from management increases uncertainty for investors.

    Key takeaways
    • Elutia is operating with a negative net worth and high debt levels, indicating significant financial distress.
    • The company's profitability metrics are weak, with a net loss and negative operating cash flow.
    • Revenue concentration in a single segment and lack of geographic diversification increase business risk.
    • Analysts have a cautiously optimistic view, with a mean price target of $5.00, but no strong buy recommendations.
    • The company's liquidity and solvency risks are high, with a current ratio of 0.63 and negative net cash.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Analysts project 423.6% upside to a $5.00 target price, signaling strong confidence in future value creation.

    Long-term debt reached zero in fiscal 2026, eliminating interest obligations and reducing financial leverage risks significantly.

    Free cash flow improved by 64.8% year-over-year in fiscal 2026, demonstrating enhanced operational cash generation capabilities.

    Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from issuance.

    BEAR CASE · 2

    Credit risk is flagged as high, indicating significant concerns regarding the company's ability to meet financial obligations.

    Cash conversion ratio of 0.15 is in the bottom quartile, indicating inefficient translation of earnings into cash.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-11
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $3.3M, +16,2% YoY; Operating income +12,0% YoY.

    Revenue$3.3M+16,2 % YoY
    Operating income-$6.6M+12,0 % YoY
    Net income$70.8M+881,3 % YoY
    Free cash flow-$7.1M−10,7 % YoY
    EPS
    Operating cash flow-$44.8M−97,8 % YoY
    Financials
    Income statement
    Revenue$3.3M
    Gross profit$1.9M
    Operating income-$6.6M
    Net income$70.8M
    Margins
    Gross margin58.5%
    Operating margin-200.6%
    Net margin2164.2%
    FCF margin-216.1%
    Balance sheet
    Total assets$62.4M
    Total liabilities$34.7M
    Total equity$27.7M
    Cash & equivalents
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$44.8M
    CapEx-$1.9M
    Free cash flow-$7.1M
    SBC
    P&L flow · revenue → net income
    Revenue $3.3MOperating costs $9.8MNet income $70.8M
    Highlights
    • Revenue $3.3M, +16,2% YoY
    • Operating income +12,0% YoY
    • Net income +881,3% YoY
    • Free cash flow −10,7% YoY
    • Net margin 2164.2%

    Valuation TTM

    Market price
    $0,87
    Market cap
    $46.0M
    Enterprise value
    $68.0M
    P/E
    0.9x
    Non-GAAP P/E
    EV / Revenue
    3.6x
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$50.3M
    Net cash
    -$22.0M
    Current ratio
    0.6
    Debt / equity
    -0.4
    ROA
    -50.9%
    ROE
    35.8%
    Cash conversion
    15.0%
    CapEx / revenue
    -0.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Acellular Dermal Matrices
    low · business_description · 2026-07-03
    Cardiovascular Repair Matrices
    low · business_description · 2026-07-03

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Pharmaceuticals1 042,4B node revenueMCK 38,7%COR 30,8%CAH 21,4%DB 3,4%REGN 1,4%BIIB 0,9%ZTS 0,9%GRFS 0,8%Other 1,7%
    Source: company disclosures · own-taxonomy revenue-covered setELUT 0,0% · rank #31 of 40

    Business relationships

    Business relationships5 disclosed relationships · 3 types · extracted from filings & disclosures
    Customers3
    ANON:CUST:ELUT.O:P10ANON:CUST:ELUT.O:P10Customer88%Source ↗
    ANON:CUST:ELUT.O:P13ANON:CUST:ELUT.O:P13Customer88%Source ↗
    ANON:CUST:ELUT.O:P18ANON:CUST:ELUT.O:P18Customer88%Source ↗
    Partners1
    Subsidiaries1
    EX21:471fb862b3fdEX21:471fb862b3fdSubsidiarie97%

    Supply chain

    Vendors → ELUT ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSELUTELUTElutia Inc5 entitiesLeMaitre Vascular, IncAdvanced Medical EquipmeUSANON:CUST:ELUT.O:P10ANON:CUST:ELUT.O:P13ANON:CUST:ELUT.O:P18
    4 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-07-04

    Peer comparison

    Peer comparison8 peers · vs ELUT · multiples and returns
    MC
    MCK
    Mckesson Corp
    $827,14
    102,6B USD
    P/E
    21,2x
    vs self
    Div yield
    0,4 %
    vs self
    ROE
    -219,2 %
    -255,0 vs self
    CO
    COR
    Cencora Inc
    $308,37
    60,2B USD
    P/E
    36,4x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    45,7 %
    +10,0 vs self
    CA
    CAH
    Cardinal Health Inc
    $235,60
    57,0B USD
    P/E
    36,7x
    vs self
    Div yield
    0,9 %
    vs self
    ROE
    -55,9 %
    -91,7 vs self
    DB
    DB
    DB.V
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    RE
    REGN
    REGENERON PHARMACEUTICALS, INC.
    $757,99
    81,0B USD
    P/E
    15,5x
    vs self
    Div yield
    vs self
    ROE
    14,2 %
    -21,6 vs self
    BI
    BIIB
    BIOGEN INC.
    $201,74
    29,6B USD
    P/E
    21,3x
    vs self
    Div yield
    vs self
    ROE
    7,5 %
    -28,3 vs self
    ZT
    ZTS
    Zoetis Inc
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    GR
    GRFS
    Grifols SA
    $7,86
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,54
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,54
    Revenueno estimateno estimate12,0M USD
    Operating incomeno estimateno estimate-24,5M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$5,00 · Median $5,00
    Low $5,00High $5,00
    Operating income · consensus-24,5M USD
    EPS surprise
    +261,1 %
    reported vs consensus · beat
    Revenue surprise
    +2,4 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$5,00
    Mean$5,00
    Median$5,00
    High$5,00
    Spot$0,87
    +476.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-126,7 %Bottom quartile
    Net Margin-268,8 %Bottom quartile
    ROE35,8 %Best in class
    Capex / Rev-0,2 %Above median
    D/E-0,44Best in class
    Cash Conv0,15Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 807 879 sh8 exercises · 7 grants7 insiders
    • Mills C RandalDirector, PRESIDENT AND CEO · Restricted Stock Units → Class A Common StockDisposed 22 473exercise · 2026-06-21
    • RAKIN KEVINDirector, 10% owner · Stock Option (Right to Buy) → Class A Common StockAcquired 159 590 @ $0,96grant · 2026-06-11
    • NEELS GUIDO JDirector · Stock Option (Right to Buy) → Class A Common StockAcquired 106 393 @ $0,96grant · 2026-06-11
    • Makes BrigidDirector · Stock Option (Right to Buy) → Class A Common StockAcquired 106 393 @ $0,96grant · 2026-06-11
    • Colpman DavidDirector · Stock Option (Right to Buy) → Class A Common StockAcquired 106 393 @ $0,96grant · 2026-06-11
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-06-10
    • Williams Michelle LeRouxCHIEF SCIENTIFIC OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-06-10
    • Mills C RandalDirector, PRESIDENT AND CEO · Restricted Stock Units → Class A Common StockDisposed 27 083exercise · 2026-06-10
    • Williams Michelle LeRouxCHIEF SCIENTIFIC OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-03-10
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-03-10
    • Mills C RandalDirector, PRESIDENT AND CEO · Restricted Stock Units → Class A Common StockDisposed 27 084exercise · 2026-03-10
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Class A Common StockAcquired 368 000 @ $0,69grant · 2026-01-01
    • Mills C RandalDirector, PRESIDENT AND CEO · Stock Option (Right to Buy) → Class A Common StockAcquired 726 000 @ $0,69grant · 2026-01-01
    • Williams Michelle LeRouxCHIEF SCIENTIFIC OFFICER · Stock Option (Right to Buy) → Class A Common StockAcquired 368 000 @ $0,69grant · 2026-01-01
    • NEELS GUIDO JDirector · Restricted Stock Units → Class A Common StockDisposed 6 250exercise · 2025-12-10

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Elutia Inc Market data — financials · 2026-05-27
    • Elutia Inc Market data — analyst estimates · 2026-05-27
    • Elutia Inc Market data — ESG · 2026-05-27

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying9 buys · 0 sellsnet $206K7 insiders · last 365d
    • Mills C RandalDirector, PRESIDENT AND CEO · Class A Common StockOther 8 064 @ $1,06$9K · 2026-06-21
    • Mills C RandalDirector, PRESIDENT AND CEO · Class A Common StockOther 22 473 · 2026-06-21
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Class A Common StockOther 12 500 · 2026-06-10
    • Mills C RandalDirector, PRESIDENT AND CEO · Class A Common StockOther 27 083 · 2026-06-10
    • Mills C RandalDirector, PRESIDENT AND CEO · Class A Common StockOther 9 718 @ $1,04$10K · 2026-06-10
    • Williams Michelle LeRouxCHIEF SCIENTIFIC OFFICER · Class A Common StockOther 4 269 @ $1,04$4K · 2026-06-10
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Class A Common StockOther 4 485 @ $1,04$5K · 2026-06-10
    • Williams Michelle LeRouxCHIEF SCIENTIFIC OFFICER · Class A Common StockOther 12 500 · 2026-06-10
    • RAKIN KEVINDirector, 10% owner · Class A Common StockOther 70 000 · 2026-06-01
    • RAKIN KEVINDirector, 10% owner · Class A Common StockOther 50 000 · 2026-06-01
    • Mills C RandalDirector, PRESIDENT AND CEO · Class A Common StockOther 11 100 @ $1,09$12K · 2026-03-10
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Class A Common StockOther 5 123 @ $1,09$6K · 2026-03-10
    • Williams Michelle LeRouxCHIEF SCIENTIFIC OFFICER · Class A Common StockOther 12 500 · 2026-03-10
    • Williams Michelle LeRouxCHIEF SCIENTIFIC OFFICER · Class A Common StockOther 4 613 @ $1,09$5K · 2026-03-10
    • Mills C RandalDirector, PRESIDENT AND CEO · Class A Common StockOther 27 084 · 2026-03-10
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Class A Common StockOther 12 500 · 2026-03-10
    • NEELS GUIDO JDirector · Class A Common StockBought 20 000 @ $1,04$21K · 2026-01-30
    • RAKIN KEVINDirector, 10% owner · Class A Common StockBought 70 000 @ $1,06$74K · 2026-01-30
    • NEELS GUIDO JDirector · Class A Common StockBought 15 000 @ $1,06$16K · 2026-01-29
    • NEELS GUIDO JDirector · Class A Common StockBought 15 000 @ $1,06$16K · 2026-01-28
    • RAKIN KEVINDirector, 10% owner · Class A Common StockBought 50 000 @ $0,52$26K · 2025-12-17
    • Colpman DavidDirector · Class A Common StockBought 12 500 @ $0,51$6K · 2025-12-17
    • Makes BrigidDirector · Class A Common StockBought 25 000 @ $0,52$13K · 2025-12-17
    • Mills C RandalDirector, PRESIDENT AND CEO · Class A Common StockBought 3 000 @ $0,51$2K · 2025-12-17
    • Ferguson MatthewCHIEF FINANCIAL OFFICER · Class A Common StockBought 60 000 @ $0,53$32K · 2025-12-17

    Short positioning

    43.0Kshares short-18.8% vs prior
    1.07days to cover
    10.8%short of daily vol
    2.8Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ELUT.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    ELUTANON:CUSANON:CUSANON:CUSLMAT.OEX21:471Diversified Ph
    This companySectorCustomersPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 174.6%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -57.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 146.8%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 72.6%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 159.8%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 38.9%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 12.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -97.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 198.9%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -26.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 169.4%Derived (calculated)
    • Return on equity (FY 2025-12-31): 192.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): 85.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 2.22xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.25xDerived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -1.8%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 186.9%Derived (calculated)
    • Cost of revenue (annual): USD 5.7MSEC XBRL filing
    • R&D expense (annual): USD 4.16MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
    • Pre-tax income (annual): USD -15.86MSEC XBRL filing
    • Total assets (annual): USD 62.35MSEC XBRL filing
    • Total liabilities (annual): USD 34.68MSEC XBRL filing
    • Cash & equivalents (annual): USD 36.35MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-21 00:00 UTCINSIDER18 insider transactions — 2026-06 8 derivative
    2026-06-21INSIDERMills C Randal transacted 8.1k sh Class A Common Stock — Director, PRESIDENT AND CEO ~$9k
    2026-06-21INSIDERMills C Randal transacted 22.5k sh Class A Common Stock — Director, PRESIDENT AND CEO
    2026-06-21INSIDERMills C Randal disposed of 22.5k sh Restricted Stock Units — Director, PRESIDENT AND CEO
    2026-06-16FILING8-K filing →
    2026-06-11INSIDERNEELS GUIDO J acquired 106.4k sh Stock Option (Right to Buy) — Director
    2026-06-11INSIDERMakes Brigid acquired 106.4k sh Stock Option (Right to Buy) — Director
    2026-06-11INSIDERRAKIN KEVIN acquired 159.6k sh Stock Option (Right to Buy) — Director, 10% owner
    2026-06-11INSIDERColpman David acquired 106.4k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERFerguson Matthew transacted 12.5k sh Class A Common Stock — CHIEF FINANCIAL OFFICER
    2026-06-10INSIDERMills C Randal transacted 27.1k sh Class A Common Stock — Director, PRESIDENT AND CEO
    2026-06-10INSIDERMills C Randal transacted 9.7k sh Class A Common Stock — Director, PRESIDENT AND CEO ~$10k
    2026-06-10INSIDERWilliams Michelle LeRoux transacted 4.3k sh Class A Common Stock — CHIEF SCIENTIFIC OFFICER ~$4k
    2026-06-10INSIDERFerguson Matthew transacted 4.5k sh Class A Common Stock — CHIEF FINANCIAL OFFICER ~$5k
    2026-06-10INSIDERWilliams Michelle LeRoux transacted 12.5k sh Class A Common Stock — CHIEF SCIENTIFIC OFFICER
    2026-06-10INSIDERFerguson Matthew disposed of 12.5k sh Restricted Stock Units — CHIEF FINANCIAL OFFICER
    2026-06-10INSIDERWilliams Michelle LeRoux disposed of 12.5k sh Restricted Stock Units — CHIEF SCIENTIFIC OFFICER
    2026-06-10INSIDERMills C Randal disposed of 27.1k sh Restricted Stock Units — Director, PRESIDENT AND CEO
    2026-06-01INSIDERRAKIN KEVIN transacted 70.0k sh Class A Common Stock — Director, 10% owner
    2026-06-01INSIDERRAKIN KEVIN transacted 50.0k sh Class A Common Stock — Director, 10% owner
    2026-05-15FILING10-Q filing →
    2026-05-14FILING8-K filing →
    2026-04-22FILINGDEF 14A filing →
    2026-03-13FILING10-K filing →
    2026-03-11 16:05 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 3.3M · Net USD 70.8M
    2026-03-11 16:05 UTCEARNINGSAnnual results — FY 2026 Revenue USD 12.3M · Net USD 53.4M
    2026-03-11FILING8-K filing →
    2026-03-10 00:00 UTCINSIDER9 insider transactions — 2026-03 3 derivative
    2026-03-10INSIDERMills C Randal transacted 11.1k sh Class A Common Stock — Director, PRESIDENT AND CEO ~$12k
    2026-03-10INSIDERFerguson Matthew transacted 5.1k sh Class A Common Stock — CHIEF FINANCIAL OFFICER ~$6k
    2026-03-10INSIDERWilliams Michelle LeRoux transacted 12.5k sh Class A Common Stock — CHIEF SCIENTIFIC OFFICER
    2026-03-10INSIDERWilliams Michelle LeRoux transacted 4.6k sh Class A Common Stock — CHIEF SCIENTIFIC OFFICER ~$5k
    2026-03-10INSIDERMills C Randal transacted 27.1k sh Class A Common Stock — Director, PRESIDENT AND CEO
    2026-03-10INSIDERFerguson Matthew transacted 12.5k sh Class A Common Stock — CHIEF FINANCIAL OFFICER
    2026-03-10INSIDERFerguson Matthew disposed of 12.5k sh Restricted Stock Units — CHIEF FINANCIAL OFFICER
    2026-03-10INSIDERMills C Randal disposed of 27.1k sh Restricted Stock Units — Director, PRESIDENT AND CEO
    2026-03-10INSIDERWilliams Michelle LeRoux disposed of 12.5k sh Restricted Stock Units — CHIEF SCIENTIFIC OFFICER
    2026-03-09FILING8-K filing →
    Showing the 40 most recent of 71 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage